Table 2.
Clinical characteristics of NPHP1 patients at the time point when classified “hypertensive”
| Characteristics | Patients |
|---|---|
| Sex | |
| Female | 27 |
| Male | 35 |
| Age at diagnosis (yrs) | 11.2 (2.4–33.4) |
| CKD stage | |
| CKD I | 2 |
| CKD II | 1 |
| CKD III | 16 |
| CKD IV | 17 |
| CKD V | 26 |
| Average time from diagnosis hypertension to ESKD (yrs) | 1.52 (0–7.1) |
| Pre-RRT antihypertensive treatment | |
| No | 14 |
| Mono | 32 |
| Dual | 8 |
| Triple | 8 |
| Calcium antagonist | 23 |
| Beta blocker | 18 |
| ACEIs | 27 |
| Other | 4 |
ACEI, angiotensin-converting enzyme inhibitor; CKD, chronic kidney disease; EKSD, end-stage kidney disease; RRT, renal replacement therapy.
Arterial hypertension was either defined by the start of antihypertensive treatment before the onset of ESKD (n = 48) or simultaneously with the start of RRT.